<h2>关键点</h2>
<ul>
<li>FDA 已批准每日服用的 Wegovy 药丸。</li>
<li>这种新版本的减肥药将在下个月上市。</li>
<li>该药丸可能会重新加速诺和诺德的收入增长，可能会点燃其被低估的股票强劲反弹。</li>
<li>我们更看好的 10 只股票 ›</li>
</ul>
<p>目前是否有比 GLP-1 激动剂肥胖药物（如 Ozempic）更受欢迎的健康趋势？可能没有。然而，讽刺的是，投资 Ozempic，或者说其制造商 <strong>诺和诺德</strong>（NYSE: NVO），今年的表现并不理想。</p>
<p>2025 年股价下跌了 40%。来自 <strong>礼来</strong>（Eli Lilly）类似药物 Zepbound 的竞争，以及销售复合版本 Ozempic 的远程医疗公司，给诺和诺德的业务施加了压力，以至于公司在今年早些时候解雇了其首席执行官。</p>
<p>投资像诺和诺德这样的冷门股票可能会让人感到有些害怕，但这家制药巨头的情况可能开始回暖。</p>
<p><img src="https://imageproxy.pbkrs.com/https://s.yimg.com/ny/api/res/1.2/FAqB0xtkNumzLLwYJ9xmRA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU3Ng--/https://media.zenfs.com/en/motleyfool.com/b34d3320a58e71aec8109b2b12047705?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="960" height="576" original-src="https://imageproxy.pbkrs.com/https://s.yimg.com/ny/api/res/1.2/FAqB0xtkNumzLLwYJ9xmRA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU3Ng--/https://media.zenfs.com/en/motleyfool.com/b34d3320a58e71aec8109b2b12047705"/></p>
<p>图片来源：诺和诺德</p>
<h2>诺和诺德刚刚获得了改变游戏规则的机会</h2>
<p>在 FDA 正式批准其在美国销售 Wegovy 药丸的申请后，诺和诺德的股价在周二大幅上涨。Wegovy 与 Ozempic 是同一种药物——通用名为 semaglutide——但后者被批准用于治疗 2 型糖尿病，而 Wegovy 是旨在用于体重管理的品牌。</p>
<p>FDA 的决定有几个重要原因。首先，Wegovy 药丸将是市场上首个口服 GLP-1 药物。在该治疗的 3 期试验中，参与者在 64 周内平均减重 16.6%，其中三分之一的人减重 20% 或更多。其次，大多数患者可能更喜欢每日服用药丸而不是注射。</p>
<p>这种新版本的药物将为诺和诺德提供一个重要工具，以应对来自竞争的压力。礼来正在寻求其口服肥胖药物的 FDA 批准，可能最早在 3 月获得批准，但诺和诺德已经赢得了市场的竞争。与此同时，Wegovy 可能会迅速获得市场认可，这将有助于诺和诺德，即使它在短期内仍然是唯一获得批准的此类药丸。</p>
<p>Wegovy 药丸将在 1 月初向患者提供，诺和诺德的首席执行官表示，公司已经建立了足够的供应以支持积极的产品发布。他说：“这次我们有足够的药丸。”</p>
<h2>股票的下跌已经蓄势待发</h2>
<p>诺和诺德的业务显然感受到了竞争的压力。其收入增长已经持续放缓超过一年。然而，根据头条新闻和股票表现，很容易相信该业务已经崩溃，但这显然不是真的。</p>
<p>事实上，诺和诺德仍在增长，包括最近一个季度的两位数百分比收入增长。自 2023 年初以来，其每股收益大约翻了一番。</p>
<p><img src="https://imageproxy.pbkrs.com/https://s.yimg.com/ny/api/res/1.2/XRYrTZA5Yg5G6L3pM9DBxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTYwOA--/https://media.zenfs.com/en/motleyfool.com/facbb040722564ba7d9a157edf957921?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="720" height="456" original-src="https://imageproxy.pbkrs.com/https://s.yimg.com/ny/api/res/1.2/XRYrTZA5Yg5G6L3pM9DBxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTYwOA--/https://media.zenfs.com/en/motleyfool.com/facbb040722564ba7d9a157edf957921"/></p>
<p>NVO 收入（季度同比增长）数据来源于 YCharts。</p>
<p>在股价下跌后，诺和诺德就像一个被压缩的弹簧——它正等待释放其积蓄的能量。该股票目前的市盈率仅为预期 2025 年收益的 13 倍。</p>
<p>即使其增长率仅稳定在低双位数百分比，这也可以说是一个便宜的价格。然而，Wegovy 药丸似乎很可能成为一个重要的催化剂，可能会在 2026 年中期重新加速公司的收入增长。</p>
<h2>诺和诺德值得购买吗？</h2>
<p>如果诺和诺德能够在未来以 15% 或更高的年化增长率提升其收益，那么这将轻松证明市场将其市盈率提升至 20 以上的合理性。</p>
<p>这意味着它可能成为明年的一项重大投资。股票估值简单反弹至 20 倍收益将意味着股价从此处上涨超过 50%，而这还不包括潜在的双位数收益增长。</p>
<p>此外，在当前股价下，该公司的股息收益率为 3.3%，接近其历史最高收益率。如果将所有因素考虑在内，诺和诺德在 2026 年有成为市场超越投资的潜力。这并不是一个保证的结果，但它应该经历的顺风因素足以让人强烈考虑在新年到来之际将该股票加入投资组合。</p>
<h2>你现在应该购买诺和诺德的股票吗？</h2>
<p>在你购买诺和诺德的股票之前，请考虑以下几点：</p>
<p><em>Motley Fool Stock Advisor</em> 分析师团队刚刚确定了他们认为的 <strong>10 只最佳股票</strong> 供投资者现在购买……而诺和诺德并不在其中。入选的 10 只股票在未来几年可能会产生巨大的回报。</p>
<p>考虑一下 <strong>Netflix</strong> 在 2004 年 12 月 17 日进入这个名单时……如果你在我们推荐时投资了 1,000 美元，<strong>你将拥有 504,994 美元</strong>！* 或者 <strong>Nvidia</strong> 在 2005 年 4 月 15 日进入这个名单时……如果你在我们推荐时投资了 1,000 美元，<strong>你将拥有 1,156,218 美元</strong>！*</p>
<p>现在，值得注意的是 <em>Stock Advisor</em> 的总平均回报率为 986%——相比于 S&amp;P 500 的 196%，表现出色。<strong>不要错过最新的前 10 名股票列表，加入由个人投资者为个人投资者建立的投资社区。</strong></p>
<p><strong>查看这 10 只股票 »</strong></p>
<p><em>*Stock Advisor 回报截至 2025 年 12 月 22 日</em></p>
<p><em>Justin Pope 在提到的任何股票中没有持仓。Motley Fool 推荐诺和诺德。Motley Fool 有披露政策。</em></p>
<p>你应该在 2026 年投资 Ozempic 制造商诺和诺德吗？最初由 Motley Fool 发布。</p>

诺和诺德公司

<p>诺和诺德公司的股票因竞争和管理变动而下滑，但 FDA 对其 Wegovy 药丸的批准，这是一种用于体重管理的口服 GLP-1 药物，可能会促进其增长。该药丸将在 1 月上市，可能帮助诺和诺德重新获得动力，预计到 2026 年可能成为一个强劲的投资。尽管面临近期挑战，该公司的收入和盈利仍在增长，其股票被认为被低估，提供 3.3% 的股息收益率。分析师建议考虑诺和诺德作为一个超越市场的投资机会</p>

<h2>Key Points</h2>
<div class="lb-trans"><h2>关键点</h2>
</div><ul>
<li>The FDA has approved a daily Wegovy pill.</li>
<li>The new version of the weight loss drug will hit the market next month.</li>
<li>The pill could reaccelerate Novo Nordisk's top-line growth, potentially igniting a strong stock comeback from its depressed valuation.</li>
<li>10 stocks we like better than Novo Nordisk ›</li>
</ul>
<div class="lb-trans"><ul>
<li>FDA 已批准每日服用的 Wegovy 药丸。</li>
<li>这种新版本的减肥药将在下个月上市。</li>
<li>该药丸可能会重新加速诺和诺德的收入增长，可能会点燃其被低估的股票强劲反弹。</li>
<li>我们更看好的 10 只股票 ›</li>
</ul>
</div><p>Is there a more popular health trend right now than GLP-1 agonist obesity drugs such as Ozempic? Probably not. Ironically, though, investing in Ozempic, or rather in its manufacturer, <strong>Novo Nordisk</strong>(NYSE: NVO), hasn't gone very well this year.</p>
<div class="lb-trans"><p>目前是否有比 GLP-1 激动剂肥胖药物（如 Ozempic）更受欢迎的健康趋势？可能没有。然而，讽刺的是，投资 Ozempic，或者说其制造商 <strong>诺和诺德</strong>（NYSE: NVO），今年的表现并不理想。</p>
</div><p>Shares have fallen by 40% in 2025. Competition from <strong>Eli Lilly</strong>'s similar drug, Zepbound, and from telehealth companies selling compounded versions of Ozempic pressured Novo Nordisk's business to the point that the company fired its CEO earlier this year.</p>
<div class="lb-trans"><p>2025 年股价下跌了 40%。来自 <strong>礼来</strong>（Eli Lilly）类似药物 Zepbound 的竞争，以及销售复合版本 Ozempic 的远程医疗公司，给诺和诺德的业务施加了压力，以至于公司在今年早些时候解雇了其首席执行官。</p>
</div><p>Investing in a cold stock like Novo Nordisk can feel a bit scary, but things could be starting to heat up again for the pharmaceutical giant.</p>
<div class="lb-trans"><p>投资像诺和诺德这样的冷门股票可能会让人感到有些害怕，但这家制药巨头的情况可能开始回暖。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://s.yimg.com/ny/api/res/1.2/FAqB0xtkNumzLLwYJ9xmRA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU3Ng--/https://media.zenfs.com/en/motleyfool.com/b34d3320a58e71aec8109b2b12047705" alt="" original-src="https://s.yimg.com/ny/api/res/1.2/FAqB0xtkNumzLLwYJ9xmRA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU3Ng--/https://media.zenfs.com/en/motleyfool.com/b34d3320a58e71aec8109b2b12047705"/></p>
<p>Image source: Novo Nordisk</p>
<div class="lb-trans"><p>图片来源：诺和诺德</p>
</div><h2>Novo Nordisk just scored a game changer</h2>
<div class="lb-trans"><h2>诺和诺德刚刚获得了改变游戏规则的机会</h2>
</div><p>Novo Nordisk shares jumped on Tuesday following news that the Food and Drug Administration (FDA) had formally approved its application to sell a pill form of Wegovy in the United States. Wegovy is the same drug as Ozempic -- generically called semaglutide -- but while the latter is approved to treat type 2 diabetes, Wegovy is the brand intended to be prescribed for weight management.</p>
<div class="lb-trans"><p>在 FDA 正式批准其在美国销售 Wegovy 药丸的申请后，诺和诺德的股价在周二大幅上涨。Wegovy 与 Ozempic 是同一种药物——通用名为 semaglutide——但后者被批准用于治疗 2 型糖尿病，而 Wegovy 是旨在用于体重管理的品牌。</p>
</div><p>The FDA's decision is a big deal for several reasons. First, the Wegovy pill will be the first oral GLP-1 drug on the market. In a phase 3 trial of the treatment, participants showed a mean weight loss of 16.6% over 64 weeks, and one in three lost 20% or more. Second, most patients will likely prefer taking a daily pill to injections.</p>
<div class="lb-trans"><p>FDA 的决定有几个重要原因。首先，Wegovy 药丸将是市场上首个口服 GLP-1 药物。在该治疗的 3 期试验中，参与者在 64 周内平均减重 16.6%，其中三分之一的人减重 20% 或更多。其次，大多数患者可能更喜欢每日服用药丸而不是注射。</p>
</div><p>This new version of the drug will give Novo Nordisk a crucial tool to push back against the pressure it has faced from competition. Eli Lilly is seeking FDA approval for its oral obesity drug, and could get it as soon as March, but Novo Nordisk has won the race to market. In the meantime, Wegovy could quickly gain traction, which would help Novo Nordisk even if it remains the only approved pill of its kind for a limited time.</p>
<div class="lb-trans"><p>这种新版本的药物将为诺和诺德提供一个重要工具，以应对来自竞争的压力。礼来正在寻求其口服肥胖药物的 FDA 批准，可能最早在 3 月获得批准，但诺和诺德已经赢得了市场的竞争。与此同时，Wegovy 可能会迅速获得市场认可，这将有助于诺和诺德，即使它在短期内仍然是唯一获得批准的此类药丸。</p>
</div><p>The Wegovy pill will be available for patients in early January, and Novo Nordisk's CEO has said the company has already built up enough supply to support an aggressive product launch. &#34;We have more than enough pills this time,&#34; he said.</p>
<div class="lb-trans"><p>Wegovy 药丸将在 1 月初向患者提供，诺和诺德的首席执行官表示，公司已经建立了足够的供应以支持积极的产品发布。他说：“这次我们有足够的药丸。”</p>
</div><h2>The stock's decline has coiled the spring</h2>
<div class="lb-trans"><h2>股票的下跌已经蓄势待发</h2>
</div><p>Novo Nordisk's business has clearly felt the heat of competition. Its revenue growth has steadily slowed for over a year. However, based on the headlines and the stock performance, it would be easy to believe that the business has collapsed, and that's simply untrue.</p>
<div class="lb-trans"><p>诺和诺德的业务显然感受到了竞争的压力。其收入增长已经持续放缓超过一年。然而，根据头条新闻和股票表现，很容易相信该业务已经崩溃，但这显然不是真的。</p>
</div><p>In fact, Novo Nordisk continues to grow, including double-digit percentage revenue growth in its most recent quarter. Its earnings per share have roughly doubled since early 2023.</p>
<div class="lb-trans"><p>事实上，诺和诺德仍在增长，包括最近一个季度的两位数百分比收入增长。自 2023 年初以来，其每股收益大约翻了一番。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://s.yimg.com/ny/api/res/1.2/XRYrTZA5Yg5G6L3pM9DBxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTYwOA--/https://media.zenfs.com/en/motleyfool.com/facbb040722564ba7d9a157edf957921" alt="" original-src="https://s.yimg.com/ny/api/res/1.2/XRYrTZA5Yg5G6L3pM9DBxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTYwOA--/https://media.zenfs.com/en/motleyfool.com/facbb040722564ba7d9a157edf957921"/></p>
<p>NVO Revenue (Quarterly YoY Growth) data by YCharts.</p>
<div class="lb-trans"><p>NVO 收入（季度同比增长）数据来源于 YCharts。</p>
</div><p>After the stock's slide, Novo Nordisk resembles a compressed spring -- it's just waiting to unleash its pent-up energy. The stock currently trades at a price-to-earnings ratio of just 13 times its expected 2025 earnings.</p>
<div class="lb-trans"><p>在股价下跌后，诺和诺德就像一个被压缩的弹簧——它正等待释放其积蓄的能量。该股票目前的市盈率仅为预期 2025 年收益的 13 倍。</p>
</div><p>That's arguably a bargain price even if its growth rate simply stabilizes at a low double-digit percentage. However, the Wegovy pill appears likely to be a significant catalyst that could reaccelerate the company's top-line growth by mid-2026.</p>
<div class="lb-trans"><p>即使其增长率仅稳定在低双位数百分比，这也可以说是一个便宜的价格。然而，Wegovy 药丸似乎很可能成为一个重要的催化剂，可能会在 2026 年中期重新加速公司的收入增长。</p>
</div><h2>Is Novo Nordisk a buy?</h2>
<div class="lb-trans"><h2>诺和诺德值得购买吗？</h2>
</div><p>If Novo Nordisk can boost its earnings at an annualized growth rate of 15% or higher moving forward, that would easily justify the market bumping its price-to-earnings ratio back above 20.</p>
<div class="lb-trans"><p>如果诺和诺德能够在未来以 15% 或更高的年化增长率提升其收益，那么这将轻松证明市场将其市盈率提升至 20 以上的合理性。</p>
</div><p>That means it could be a home run investment next year. A simple rebound in the stock's valuation to 20 times earnings would equate to a share price gain of more than 50% from here, and that's without factoring in potential double-digit earnings growth.</p>
<div class="lb-trans"><p>这意味着它可能成为明年的一项重大投资。股票估值简单反弹至 20 倍收益将意味着股价从此处上涨超过 50%，而这还不包括潜在的双位数收益增长。</p>
</div><p>Additionally, at the current share price, the company's dividend yields 3.3%, which is near its highest yield on record. If you add it all up, Novo Nordisk has the makings of a market-beating investment in 2026. That's not a guaranteed outcome, but the tailwinds it should experience are more than enough reason to strongly consider adding the stock to your portfolio heading into the new year.</p>
<div class="lb-trans"><p>此外，在当前股价下，该公司的股息收益率为 3.3%，接近其历史最高收益率。如果将所有因素考虑在内，诺和诺德在 2026 年有成为市场超越投资的潜力。这并不是一个保证的结果，但它应该经历的顺风因素足以让人强烈考虑在新年到来之际将该股票加入投资组合。</p>
</div><h2>Should you buy stock in Novo Nordisk right now?</h2>
<div class="lb-trans"><h2>你现在应该购买诺和诺德的股票吗？</h2>
</div><p>Before you buy stock in Novo Nordisk, consider this:</p>
<div class="lb-trans"><p>在你购买诺和诺德的股票之前，请考虑以下几点：</p>
</div><p>The <em>Motley Fool Stock Advisor</em> analyst team just identified what they believe are the <strong>10 best stocks</strong> for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.</p>
<div class="lb-trans"><p><em>Motley Fool Stock Advisor</em> 分析师团队刚刚确定了他们认为的 <strong>10 只最佳股票</strong> 供投资者现在购买……而诺和诺德并不在其中。入选的 10 只股票在未来几年可能会产生巨大的回报。</p>
</div><p>Consider when <strong>Netflix</strong> made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, <strong>you’d have $504,994</strong>!* Or when <strong>Nvidia</strong> made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, <strong>you’d have $1,156,218</strong>!*</p>
<div class="lb-trans"><p>考虑一下 <strong>Netflix</strong> 在 2004 年 12 月 17 日进入这个名单时……如果你在我们推荐时投资了 1,000 美元，<strong>你将拥有 504,994 美元</strong>！* 或者 <strong>Nvidia</strong> 在 2005 年 4 月 15 日进入这个名单时……如果你在我们推荐时投资了 1,000 美元，<strong>你将拥有 1,156,218 美元</strong>！*</p>
</div><p>Now, it’s worth noting <em>Stock Advisor’s</em> total average return is 986% — a market-crushing outperformance compared to 196% for the S&amp;P 500. <strong>Don't miss the latest top 10 list, available with <em>Stock Advisor</em>, and join an investing community built by individual investors for individual investors.</strong></p>
<div class="lb-trans"><p>现在，值得注意的是 <em>Stock Advisor</em> 的总平均回报率为 986%——相比于 S&amp;P 500 的 196%，表现出色。<strong>不要错过最新的前 10 名股票列表，加入由个人投资者为个人投资者建立的投资社区。</strong></p>
</div><p><strong>See the 10 stocks »</strong></p>
<div class="lb-trans"><p><strong>查看这 10 只股票 »</strong></p>
</div><p><em>*Stock Advisor returns as of December 22, 2025</em></p>
<div class="lb-trans"><p><em>*Stock Advisor 回报截至 2025 年 12 月 22 日</em></p>
</div><p><em>Justin Pope has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.</em></p>
<div class="lb-trans"><p><em>Justin Pope 在提到的任何股票中没有持仓。Motley Fool 推荐诺和诺德。Motley Fool 有披露政策。</em></p>
</div><p>Should You Invest in Ozempic Maker Novo Nordisk in 2026? was originally published by The Motley Fool</p>
<div class="lb-trans"><p>你应该在 2026 年投资 Ozempic 制造商诺和诺德吗？最初由 Motley Fool 发布。</p>
</div>

您是否应该在 2026 年投资 Ozempic 的制造商诺和诺德公司？